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Background: Fibromyalgia (FM) is conceptualized as a central sensitization (CS) condition, that presents high serum
brain-derived neurotrophic factor (BDNF) and neuroglia activation. Although the S100B protein regulates neuroglia
functions, it has been traditionally used as a proxy of central nervous system damage. However, neither BDNF nor
S100B association with the clinical picture of FM has been elucidated. To explore their association with the
pressure-pain threshold (PPT) in FM, we performed a cross-sectional study, including 56 females with confirmed FM
aged 18–65 years. Linear regression models were used to adjust for potential confounding factors between serum
BDNF, S100B and PPT.
Results: Serum BDNF and S100B were correlated (Spearman’s Rho = 0.29). Serum BDNF (log) and S100B (log) were
correlated with the PPT (log) (Partial η2 = 0.129, P = 0.012 for the BDNF (log), and Partial η2 = 0.105, P = 0.025 for the
S100B (log)). Serum BDNF (log) was inversely associated with PPT (log) (β = −1.01, SE = 0.41), age (β = −0.02,
SE = 0.15) and obsessive compulsive disorder (β = −0.36, SE = 0.15), while serum S100B (log) was inversely associated
with PPT (log) (β = −1.38, SE = 0.50), only.
Conclusions: Both neuroglia key mediators in the CS process were inversely correlated with the PPT. Serum
assessment of BDNF and S100B deserve further study to determine its potential as a proxy for the CS spectrum
in FM.
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Fibromyalgia (FM) is estimated to affect between 1.6%
[1] and 6.4% [2] of the population, and is characterized
by widespread chronic pain accompanied by fatigue, non-
satisfying sleep and cognitive symptoms [3]. Although its
pathophysiology is not fully understood, abnormalities in
pain processing [4] related to central sensitization (CS)
and a reduced descending pain modulation with sensory
amplification [5,6] have been recognized as components
of FM. In the CS model, pain hypersensitivity and en-
hanced receptive field characteristics of the disease [7]
may be explained as a consequence of increased neuronal* Correspondence: caumo@cpovo.net
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unless otherwise stated.membrane excitability, synaptic facilitation and nocicep-
tive pathway disinhibition mediated at the molecular level
by the modification of receptor kinetics (e.g., N-methyl-
D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA)) [8] and at the cellular
level by the interaction of both neurons and microglia
interchanging neurotransmitters and inflammatory cy-
tokines (e.g., substance P, tumor necrosis factor alpha,
and brain-derived neurotrophic factor (BDNF)), which
results in enhanced neuronal and nociceptive pathway
functions [8-10].
BDNF is a neurotrophic factor that is widely distributed
in the central nervous system (CNS) and is capable of
strengthening excitatory (glutamatergic) synapses as well
as weakening inhibitory (GABAergic) synapses [11]. In the
context of CS, microglial cells activated by astrocytes canl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Zanette et al. Molecular Pain 2014, 10:46 Page 2 of 9
http://www.molecularpain.com/content/10/1/46also release BDNF, which reduces the expression of the
Cl−-cotransporter K+-Cl− exporter (KCC2) in the dorsal
horn. This results in the accumulation of intracellular
Cl−, which further limits the GABAergic inhibitory ef-
fect on these nociceptors, thereby promoting disinhib-
ition [8]. BDNF produced in the CNS is transported
through the blood–brain barrier via saturable systems
[12-14], and contributes to 70-80% of circulating BDNF
[15]. Although circulating levels of BDNF have been
found to be elevated in FM compared with controls, its
association with the patients’ clinical complaints re-
mains elusive.
Despite known role of astrocytes and microglia in the
CS [16], surrogates of their activity other than BDNF
have been scarcely explored in FM patients. S100B is a
Ca2+-binding protein that, at higher concentrations,
upregulates Interleukin-1β and Tumor Necrosis Factor
α expression and activates the Nuclear Factor kappa-
light-chain-enhancer of activated B cells (NF-kB) via the
receptor for advanced glycation end products (RAGE)
in microglia and astrocytes [17,18], all of which are in-
volved in CS progression and maintenance [8]. Elevated
S100B serum levels have been correlated with mood disor-
ders [19] and have been studied as an outcome predictor
in severe traumatic brain injury [20,21] but have not been
previously explored in a chronic pain syndrome.
Thus, considering that both BDNF and S100B play rele-
vant roles in CS and that both factors can be assessed in
serum, we hypothesized that 1) serum levels of both
BDNF and S100B may be associated with FM, and 2) both
serum mediators could have an association with the
pressure-pain threshold (PPT). To test our hypotheses, we
performed a cross-sectional study of FM patients, exam-
ined their serum BDNF and S100B levels, and evaluated
their clinical and algometrical characteristics.
Results
Two hundred and seventy-one patients were screened,
and 215 patients were excluded (205 patients did not meet
the inclusion criteria, and 10 of the patients did not con-
sent to participate). Fifty-six subjects were included in the
final analysis. The demographic and clinical characteristics
of the sample are described in Table 1. The assessed
levels of serum BDNF and S100B are described in
Table 2. Both serum BDNF and S100B showed a signifi-
cant non-parametric correlation (Spearman’s Rho = 0.289,
P = 0.031), which means that the patients with higher
BDNF presented higher S100B (Figure 1).
To study the potential effect of confounders, mul-
tiple linear regressions were performed independently
using the logarithmic transformation of both BDNF
and S100B as dependent variables and the clinical
characteristics with the potential confounding effect as
covariates, including age, body mass index (BMI), yearsof education, employment status, smoking status, use
of alcohol (yes/no), diagnosis of arterial hypertension,
psychiatric diagnoses according to the MINI, frequency
of use of over-the-counter analgesics, mean pain on the
visual analog scale on the 0–100 mm scale (VAS0–100),
score on the Pittsburgh Sleep Quality Index (PSQI), score
on the Hamilton Depression Rating Scale (HDRS), Pain
Catastrophizing Scale score adapted for the Brazilian popu-
lation (B-PCS) and its dominions, the Fibromyalgia Impact
Questionnaire (FIQ), the PPT (log), the Widespread Pain
Index (WPI) and the Symptom Severity (SS) scale score.
Variables that were independently correlated with BDNF
(log) and S100B (log) significant in the multiple linear re-
gression models included age, log PPT and obsessive com-
pulsive disorder according to the MINI. These variables
were subsequently entered as independent variables in the
multivariate linear regression model, where both BDNF
and S100B logarithmic transformations were entered as
dependent variables. The analysis showed a significant
correlation between the PPT (log) (Wilks’ λ = 0.809, F =
5.306 P = 0.009, Partial η2 = 0.191) and obsessive com-
pulsive disorder (Wilks’ λ = 0.864, F = 3.553 P = 0.037,
Partial η2 = 0.136) (Table 3).
Estimators of the association in the multivariate model
are presented in Table 3. Both serum mediators were in-
versely correlated with PPT (log). Scatter plots of the raw
PPT, BDNF and S100B are presented for illustrative pur-
poses in Figure 2, showing that an inverse non-parametric
correlation between them and the PPT was also presented.
Such non-parametric correlation means that patients with
greater PPT had lower serum mediators. The PPT (log)
(Cohen’s f2 = 0.23) had medium effect size for the BDNF
(log), and a small effect size for the S100B (log) (Cohen’s
f2 = 0.16). Although the WPI presented a non-parametric
correlation with the PPT (log) (Spearman’s Rho = −0.506,
P < 0.001) it was not correlated with BDNF (Spearman’s
Rho = 0.105, P = 0.465) nor S100B (Spearman’s Rho =
0.260, P = 0.065).
Discussion
Our results support the hypothesis of a correlation be-
tween serum BDNF and S100B in FM patients and their
association with PPT. This is the first report of serum
S100B levels in a human FM sample and its association
with another mediator of CS, serum BDNF. Further-
more, we observed that both serum BDNF and S100B
were higher in FM patients with lower PPT.
To the best of our knowledge, this is the first study to
assess serum S100B in a human sample with FM. In ani-
mal models of hyperalgesia induced by chronic restraint
and with unpredictable stress, serum S100B was found to
be consistently elevated, although its concentration was
not related to brain tissue levels [22,23]. Nevertheless, in
healthy female humans, serum S100B has been correlated
Table 2 Serum concentration of BDNF and S100B (n = 56)
Serum marker Median (Q25–75) Mean ± SD
S100B (pg/mL) 14.42 (8.78 - 19.77) 16.15 ± 9.57
BDNF (ng/mL) 43.37 (30.03 - 69.99) 49.72 ± 24.84
Table 1 Characteristics of the sample (n = 56)
Characteristic Mean ± SD
Age (years) 48.78 ± 7.91
Body mass index (kg/m2) 27.38 ± 3.89
Years of education (median (Q25–75)) 11 (6–14)
Number of trigger points (median (Q25–75)) 14 (13–16)
Employed (yes/no) 41/15
Smoking (yes/no) 4/52
Alcohol use (yes/no) 7/49
Psychiatric disorder according to the MINI (yes/no)*
Major depressive episode 32/23







Obsessive compulsive disorder 12/43
Post-traumatic stress disorder 3/52
Psychotic syndrome 1/54
Generalized anxiety disorder 28/27
Maniac-depressive disorder 2/53
Psychotropic drugs (yes/no)** 38/18
Tricyclic antidepressant (yes/no) 24/15
Selective serotonin reuptake inhibitor (yes/no) 10/28
Benzodiazepine 4/35
Other chronic disease (yes/no) 28/28
Hypertension (yes/no) 14/42
Type 2 Diabetes Mellitus (yes/no) 1/55
Asthma (yes/no) 14/42
Number of analgesic doses used per week (median (Q25–75)) 14 (7–21)
Widespread Pain Index (WPI) 15.11 ± 2.04
Symptom Severity (SS) Scale Score 7.43 ± 1.51
Pain on the VAS 70.21 ± 14.54
Pittsburgh Sleep Quality Index 22.09 ± 7.35
Hamilton Depression Rating Scale 19.93 ± 5.81
Pain Catastrophizing Scale (B-PCS) score 30.73 ± 11.65
Hopelessness 11.38 ± 4.91
Magnification 12 (7–15)
Rumination 8.14 ± 2.42
Pressure pain threshold (kg/cm2) 2.09 ± 0.23
Fibromyalgia Impact Questionnaire 61.20 ± 12.82
*Patients could have none or more than one psychiatric disorder. One patient
missed the interview for the Mini International Neuropsychiatric Interview
(MINI) application.
**Some patients were using more than one type of drug.
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the frontal, parietal, corpus callosum, dorsolateral pre-
frontal, and temporal white matter [24,25], and, to a lesser
degree, in the dorsolateral prefrontal and temporal corti-
ces [25]. Thus, the serum levels of S100B may represent
white matter structural changes, which, at the cellular
level, indicate that this serum mediator might be a proxy
of neuroglia changes. Thus, the indirect assessment of CS
is valuable because it would demonstrate the role of
neuroglia in this pathological phenomenon [16]. Although
astrocytic S100B has been correlated with serotonergic
drug activity [19,26], our study did not assess neither
adjust for serotonergic parameters or psychotropic drugs
to address this possible correlation in the present sample.
BDNF had previously been studied in FM, and although
its serum [27,28], plasma [29] and cerebrospinal fluid [30]
levels have been consistently found to be elevated com-
pared with controls, its association with PPT has not been
previously reported in FM. A relationship between BDNF
and the PPT has been previously described in healthy vol-
unteers, and its direction is dependent on gender, where
females exhibit proportional PPT and BDNF, while males
demonstrate an inverse relationship [31]. Although our
female FM sample had a response that contrasted to
that found in healthy females and was similar to the
samples of healthy males, we cannot exclude the possi-
bility that menopause could be involved in the observed
effect, due to the mean age of our sample and the lack
of control for hormonal levels in our study [31]. The
serum BDNF relationship with PPT may be tracked at
different levels, because BDNF is widely distributed in
the CNS and its binding to its high-affinity trkB recep-
tor enhances C fiber-evoked responses, thereby activat-
ing signaling pathways in the spinothalamic track and
subsequently strengthening excitatory synapses while
promoting disinhibition of descending pathways [8].
Using different neuroimaging approaches (i.e., mag-
netoencephalograpy (MEG) [32], functional magnetic
resonance imaging (fMRI) [33], proton magnetic reson-
ance spectroscopy (H-MRS) [34]), it has been shown that
lower PPT is correlated with higher brain activation in FM
compared to controls. Lower PPT has also been associated
with higher concentrations of glutamate within the poster-
ior insula, which supports the finding of enhanced excita-
tory neurotransmission in FM [34]. Furthermore, single
nucleotide polymorphisms (SNPs) in the gene encoding
the catechol-O-methyltransferase (COMT) (i.e., met/met
genotype Val158Met SNP), which has also been postulated
Figure 1 Scatter plots of serum S100B and BDNF.
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related with lower PPT [35]. Taken together, these find-
ings support the validity of using PPT in FM as a proxy
for these hypothesized pathophysiological mechanisms.
Our results further suggest that the PPT might also rep-
resent the CS mechanisms involved in FM, because
lower PPT is correlated with higher BDNF and S100B,
which are mediators involved in CS. Also, the WPI was
inversely correlated with the PPT, indicating that those
with lower threshold tend to present greater number of
painful areas.
Other clinical characteristics were also correlated with
serum BDNF and S100B. The inverse correlation of age
with BDNF has been previously described in healthy
subjects [28] but not in FM patients. As a component ofTable 3 Multivariate linear regression model of the associatio
including the pressure-pain threshold (n = 56)
Dependent variable Type III sum of squares df
BDNF (log) 4.369 3






Obsessive compulsive disorder −0.36
S100B (log)
Intercept 3.66
PPT (log) −1.38the regression modeling, the effect of other confounders
on the association between PPT and serum mediators
was adjusted. In more than half of our sample, a major
depression disorder in the MINI was identified, thereby
representing a higher prevalence than previously reported
in a Canadian representative survey [36]. Nevertheless,
these differences may be attributed to different diagnostic
and sampling methods employed by the study. Import-
antly, chronic pain is strongly associated with depressive
symptoms [37,38], which limits the extent to which this
potential confounding factor may be controlled, because
it is a component of chronic pain syndromes. Psychi-
atric disorders are expected to affect the association of
the PPT and serum mediators studied; however, only the
obsessive compulsive disorder, which is a component ofn between serum BDNF, S100B and clinical parameters,
Mean square F P Partial eta squared
1.456 7.855 0.001 0.339
1.033 3.583 0.021 0.189
SEM t P Partial eta squared
0.43 12.77 <0.001 0.760
0.41 −2.62 0.012 0.129
0.15 −2.31 0.025 0.104
0.15 −2.42 0.019 0.113
0.37 9.89 <0.001 0.189
0.50 −2.78 0.008 0.105
Figure 2 Scatter plot of the correlation between the pressure-pain threshold and serum BDNF (A) and serum S100B (B).
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serum BDNF. Although other studies have failed to
demonstrate that serum BDNF levels differ between FM
and controls with comparable anxiety levels [28], we
cannot conclude that anxiety itself [39] or the associ-
ated antidepressant drugs [27] used had an effect on
both BDNF and S100B levels. Because we only recruited
females in our sample, care should be taken when ex-
trapolating for the male population because the associ-
ation of BDNF with PPT is correlated with gender in
healthy subjects [31] and male FM patients present
lower PPT compared to females [40].Because CS is conceptualized as a continuum pheno-
menon in which FM lies at one of its extremes [41] and
PPT is proportionally associated with alterations in gen-
etic and cortical activation in the FM, our findings sug-
gest that the serum assessment of BDNF and S100B
may also be considered as a proxy of the CS spectrum
in FM. A serum test related to CS and available for cli-
nicians would provide patients and caregivers with an
additional tool to improve their understanding of FM,
and would help to alleviate the burden of suffering or
accompanying a condition that is unfortunately socially
perceived as occurring “all in the head” of patients. The
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for the inference of causality, and thus, future studies are
required to determine how these mediators may be re-
sponsible of the reduction in PPT in FM patients, and if
they may represent biomarkers for this condition. Besides
that, because our study did not include healthy controls,
care must be taken regarding generalization out of the FM
population. Also, it is worth noting that as expected for
the characteristics of the disease, plenty of patients in our
sample used psychotropic drugs including antidepressants,
which have been associated with modulation of the BDNF
[27]. Taken together, these findings may be applicable for
clinical use to define therapeutic approaches, particularly
considering that PPT is a quantitative clinical tool to as-
sess tenderness and sensitization in FM with good repro-
ducibility and discrimination ability [22-24]. Because
genetic [25] and neuroimaging studies [26-28] have con-
sistently shown its association with changes attributed to
the CS, PPT may also be considered as a powerful tool for
translational purposes in FM research.
Conclusions
This study provides additional evidence supporting the
existence of a relationship between serum S100B and
BDNF in FM and brings attention towards their value as
clinical tools to assess CS. Taken together, these results
suggest that similar to the BDNF, S100B serum levels
may also be studied as a proxy of CS mechanisms in
FM, raising the possibility of further exploration of its
potential use as a biomarker in CS syndromes.
Methods
The Methods and Results sections are reported according
to STROBE guidelines [42]. All patients provided written
informed consent prior to their participation in this study,
and the protocol was approved by the Research Ethics
Committee at the Hospital de Clínicas de Porto Alegre
(HCPA) (Institutional Review Board IRB 0000921), ac-
cording to the Declaration of Helsinki (Resolution 196/96
of National Health Council).
Study design, settings and participants
A cross-sectional study was performed at HCPA, Brazil,
between March 2011 and December 2013. Subjects were
invited from the outpatient clinics of Physical Medicine
& Rehabilitation at HCPA, and by newspaper advertise-
ment. Adult female patients with a diagnosis of FM were
invited to participate. We included patients with FM
diagnosis confirmed by an experienced physiatrist (SAZ)
according to the criteria of the American College of
Rheumatology [3] and who had pain on the visual analog
scale (VAS 0–100 mm) equal to or higher than 50 mm
during one week preceding the assessment. To assess
pain on the VAS0-100mm, patients were presented acontinuous 100 mm line and were asked to mark the
point that best represented their mean pain during most
of the time of the past week, where 0 mm represented
no pain at all and 100 mm represented the worst pain
ever. A psychiatric interview was also performed on pa-
tients to screen for potential disorders; however, patients
were not excluded based on these diagnoses. Exclusion
criteria were evidence of inflammatory rheumatic dis-
ease, autoimmune disorder, and history of substance
abuse, neurological or oncologic disease, ischemic heart
disease, kidney or hepatic insufficiency.
Dependent variables
The dependent variables of interest were serum BDNF
and serum S100B. Biological samples were collected early
in the morning. All the materials were obtained in plastic
tubes and centrifuged for 10 minutes at 4500 rpm at 4°C.
Serum was frozen at −80°C until further analyses. Serum
mediator concentrations were determined using BDNF
(Chemicon/Millipore, catalog no. CYT306, lower detec-
tion limit of the kit = 7.8 pg/mL) and S100B (Millipore,
Missouri, USA, catalog no. EZHS100B-33 K, lower detec-
tion limit of the kit = 2.7 pg/mL) enzyme-linked immuno-
sorbent assay (ELISA) kits, according to the manufacturers’
instructions.
Independent variables
After gathering biological samples an interview to address
all the questionnaires was performed. Diagnoses of psychi-
atric disorders were performed according to the criteria of
the psychiatrist interviewer using the MINI screening
questionnaire. All of the psychological tests used in this
study had been validated for the Brazilian population and
were applied by a physiatrist experienced in the adminis-
tration of these tests. The patients’ baseline depressive
symptoms were assessed using the Hamilton Depression
Rating Scale (HDRS). The pain catastrophizing scale vali-
dated for the Brazilian population (B-PCS) was a self-
administered questionnaire that consisted of 13 items to
assess the extent of the patients’ catastrophizing thoughts
and behaviors, with a score ranging from 0 to 52 [43].
Sleep quality was assessed using the Pittsburgh Sleep
Quality Index (PSQI) [44]. Demographic data and medical
comorbidities were assessed using a standardized ques-
tionnaire from our laboratory. Analgesic use was assessed
by the number of doses used weekly within the last
3 months. The Fibromyalgia Impact Questionnaire (FIQ)
was applied because it is a disease-specific questionnaire
that has been validated for use in the Brazilian population
[45]. It consists of 10 domains, and the maximum possible
score is 100.
To assess the pressure-pain threshold (PPT), patients
were asked to differentiate the perception of pressure
versus the perception of “onset of pain”. The patients
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tion of pain began. The investigator (SAZ) assessing the
PPT was trained and unable to view the display of pres-
sure intensities. An electronic algometer (J Tech Medical
Industries, USA) was used. The device consisted of a 1-cm2
hard-rubber probe, which was applied over all of the tender
points. The average values of the PPT in kgf/cm2 (lb/cm2)
for three successive readings were obtained at intervals of
3–5 min and used as outcomes. The number of tender
points was determined using the PPT in the classical
areas previously described by the American College of
Rheumatology for FM criteria [46].
Efforts to address potential sources of bias
To reduce assessment bias, only one researcher (SAZ)
was involved in all of the assessments with the exception
of the MINI, which in turn was applied by one psych-
iatrist. The evaluator (SAZ) is a practicing physiatrist of
the outpatient clinic at HCPA with vast clinical expertise,
who is well trained in the application of clinical scales and
PPT assessment, as well as in the care of chronic pain pa-
tients. The algometer used (J Tech Medical Industries,
USA) was calibrated and was acquired from a recognized
provider in Brazil.
Sample size
Considering type I and II errors of 0.05 and 0.20, re-
spectively, and anticipating an effect size (f2) of 0.25 for
multiple regression analysis, which allows for four pre-
dictors [47], a sample size of 53 patients was estimated.
A sample of 56 patients was determined to account for
unexpected factors, which would decrease the study
power and increase the increased variability of our sam-
ple or missing data.
Statistical methods
Conventional central tendency statistics were used to
summarize and present the main features of the sample.
Distribution of the variables was tested using the Shapiro-
Wilk test. Non-normally distributed variables were sub-
jected to logarithmic transformation. After confirming
the corresponding assumptions, linear regression ana-
lysis with forward selection controlling for co-linearity
[48] and autocorrelation (Durbin-Watson test) was per-
formed to identify potential confounders in the association
between the main independent variables of interest (i.e.,
clinical scales and PPT) and serum markers (i.e., BDNF
and S100B). The covariates included in the model were
those that presented a correlation coefficient equal to or
higher than 0.3 with a P-value <0.15, including age, body
mass index, years of education, employment status, smok-
ing status, alcohol use, diagnosis of arterial hypertension,
presence of psychiatric diagnosis according to the Mini
International Neuropsychiatric Interview (MINI), theWidespread Pain Index (WPI), the Symptom Severity
(SS) scale score according to the ACR 2010 FM diag-
nostic criteria, and the number of analgesic doses used
per week. Each MINI potential diagnosis was entered in
the model as a dichotomous variable, where having a
diagnosis (i.e., major depression, major depression with
dysthymia, dysthyma, suicidal risk, hypo-maniac episode,
panic disorder, agoraphobia, social phobia, obsessive
compulsive disorder, post-traumatic stress disorder, al-
cohol dependence or abuse, non-alcoholic substance abuse,
psychotic syndrome, nervous anorexia, nervous bulimia,
anti-social personality disorder, or maniac-depressive dis-
order) was coded as 1 or 0 otherwise. Only covariates
(PPT, age, and obsessive compulsive disorder) that were
retained in each model were included in the final multi-
variate linear regression model with both serum markers
as dependent variables (i.e. BDNF and S100B). Cohen’s f2
effect size was calculated using an effect size calculator for
multiple regressions given the values of R2 [47]. The alpha
level was set at 0.05. The data were analyzed using SPSS
version 18.0 (SPSS, Chicago, IL).
Abbreviations
UFRGS: Universidade Federal do Rio Grande do Sul; HCPA: Hospital de
Clínicas de Porto Alegre; FM: Fibromyalgia; CS: Central Sensitization;
BDNF: Brain-Derived Neurotrophic Factor; PPT: Pressure-Pain Threshold;
NMDA: N-Methyl-D-Aspartate; AMPA: α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; CNS: Central Nervous System; KCC2: Chloride-
cotransporter Potassium and Chloride exporter; GABA: Gamma-Aminobutyric
Acid; RAGE: Receptor for advanced glycation end products; BMI: Body mass
index; MINI: Mini International Neuropsychiatric Interview; PSQI: Pittsburgh
Sleep Quality Index; HDRS: Hamilton Depression Rating Scale; B-PCS: Pain
Catastrophizing Scale validated for the Brazilian population; FIQ: Fibromyalgia
Impact Questionnaire; ELISA: Enzyme-linked immunosorbent assay.
Competing interests
The authors declare that there are no financial or other relationships that
might lead to conflicts of interest for any of the following arrangements:
financial relationship to the work; employees of a company; consultants for a
company; stockholders of the company; members of a speaker’s bureau or
any other financial form.
Authors’ contributions
WC, ILST and SAZ conceived and designed the study. SAZ, AS and AD
acquired data. JAD-S, ILST and WC analyzed and interpreted the data. WC,
SAZ and JAD-S drafted the manuscript. All of authors have read and
approved the final manuscript.
Acknowledgements
This study was supported by grants and material support obtained from the
following Brazilian agencies: Committee for the Development of Higher
Education Personnel – CAPES - PNPD/CAPES (grants to de Souza A, Deitos A)
and material support; National Council for Scientific and Technological
Development - CNPq ( grants to Dussan-Sarria JA, Torres ILS, Caumo W);
Postgraduate Program in Medical Sciences at the School of Medicine of the
Federal University of Rio Grande do Sul (material support);Postgraduate
Research Group at the Hospital de Clínicas de Porto Alegre (material
support); and the Foundation for Support of Research at Rio Grande do Sul
(FAPERGS) (grant to Caumo W).
Author details
1Physical Medicine and Rehabilitation Service at Hospital de Clínicas de Porto
Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto
Alegre, Brazil. 2Post Graduate Program in Medical Sciences, UFRGS, Porto
Zanette et al. Molecular Pain 2014, 10:46 Page 8 of 9
http://www.molecularpain.com/content/10/1/46Alegre, Brazil. 3Laboratory of Pain & Neuromodulation, HCPA/UFRGS, Porto
Alegre, Brazil. 4Pain and Palliative Care Service at HCPA/UFRGS, Porto Alegre,
Brazil. 5Universitary Center Unilasalle, Canoas, Brazil. 6Pharmacology
Department, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre,
Brazil.
Received: 10 March 2014 Accepted: 3 July 2014
Published: 8 July 2014References
1. Perrot S, Vicaut E, Servant D, Ravaud P: Prevalence of fibromyalgia in
France: a multi-step study research combining national screening and
clinical confirmation: The DEFI study (Determination of Epidemiology of
FIbromyalgia). BMC Musculoskelet Disord 2011, 12:224.
2. Vincent A, Lahr BD, Wolfe F, Clauw DJ, Whipple MO, Oh TH, Barton DL, St
Sauver J: Prevalence of fibromyalgia: a population-based study in
Olmsted County, Minnesota, utilizing the Rochester Epidemiology
Project. Arthritis Care Res (Hoboken) 2013, 65:786–792.
3. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell
AS, Russell IJ, Winfield JB, Yunus MB: The American College of
Rheumatology preliminary diagnostic criteria for fibromyalgia and
measurement of symptom severity. Arthritis Care Res (Hoboken) 2010,
62:600–610.
4. Bennett R: Fibromyalgia: present to future. Curr Rheumatol Rep 2005,
7:371–376.
5. Staud R, Rodriguez ME: Mechanisms of disease: pain in fibromyalgia
syndrome. Nat Clin Pract Rheumatol 2006, 2:90–98.
6. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD: Abnormal
sensitization and temporal summation of second pain (wind-up) in
patients with fibromyalgia syndrome. Pain 2001, 91:165–175.
7. Woolf CJ: Central sensitization: implications for the diagnosis and
treatment of pain. Pain 2011, 152:S2–S15.
8. Latremoliere A, Woolf CJ: Central sensitization: a generator of pain
hypersensitivity by central neural plasticity. J Pain 2009, 10:895–926.
9. Kawasaki Y, Zhang L, Cheng JK, Ji RR: Cytokine mechanisms of central
sensitization: distinct and overlapping role of interleukin-1beta,
interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and
neuronal activity in the superficial spinal cord. J Neurosci 2008,
28:5189–5194.
10. Taves S, Berta T, Chen G, Ji RR: Microglia and spinal cord synaptic
plasticity in persistent pain. Neural Plast 2013, 2013:753656.
11. Binder DK, Scharfman HE: Brain-derived neurotrophic factor. Growth
Factors 2004, 22:123–131.
12. Asmundson GJ, Norton PJ, Norton GR: Beyond pain: the role of fear and
avoidance in chronicity. Clin Psychol Rev 1999, 19:97–119.
13. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived
neurotrophic factor across the blood–brain barrier. Neuropharmacology
1998, 37:1553–1561.
14. Poduslo JF, Curran GL: Permeability at the blood–brain and blood-nerve
barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res
Mol Brain Res 1996, 36:280–286.
15. Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, Secher NH,
Pedersen BK, Pilegaard H: Evidence for a release of brain-derived
neurotrophic factor from the brain during exercise. Exp Physiol 2009,
94:1062–1069.
16. Ikeda H, Kiritoshi T, Murase K: Contribution of microglia and astrocytes to
the central sensitization, inflammatory and neuropathic pain in the
juvenile rat. Mol Pain 2012, 8:43.
17. Bianchi R, Giambanco I, Donato R: S100B/RAGE-dependent activation of
microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by
S100B, IL-1beta and TNF-alpha. Neurobiol Aging 2010, 31:665–677.
18. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL:
Functions of S100 proteins. Curr Mol Med 2013, 13:24–57.
19. Schroeter ML, Abdul-Khaliq H, Sacher J, Steiner J, Blasig IE, Mueller K: Mood
disorders are glial disorders: evidence from in vivo studies. Cardiovasc
Psychiatry Neurol 2010, 2010:780645.
20. Kleindienst A, Schmidt C, Parsch H, Emtmann I, Xu Y, Buchfelder M: The
passage of S100B from brain to blood is not specifically related to the
blood–brain barrier integrity. Cardiovasc Psychiatry Neurol 2010,
2010:801295.21. Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, Edwards M,
Rosmalen CF, Vissers JL: GFAP and S100B are biomarkers of traumatic
brain injury: an observational cohort study. Neurology 2010, 75:1786–1793.
22. Imbe H, Kimura A, Donishi T, Kaneoke Y: Effects of restraint stress on glial
activity in the rostral ventromedial medulla. Neuroscience 2013, 241:10–21.
23. Luo KR, Hong CJ, Liou YJ, Hou SJ, Huang YH, Tsai SJ: Differential regulation
of neurotrophin S100B and BDNF in two rat models of depression. Prog
Neuropsychopharmacol Biol Psychiatry 2010, 34:1433–1439.
24. Streitburger DP, Arelin K, Kratzsch J, Thiery J, Steiner J, Villringer A, Mueller K,
Schroeter ML: Validating serum S100B and neuron-specific enolase as
biomarkers for the human brain - a combined serum, gene expression
and MRI study. PLoS One 2012, 7:e43284.
25. Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, Keilhoff G,
Bogerts B: Evidence for a wide extra-astrocytic distribution of S100B in
human brain. BMC Neurosci 2007, 8:2.
26. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE: Serum
markers support disease-specific glial pathology in major depression.
J Affect Disord 2008, 111:271–280.
27. Laske C, Stransky E, Eschweiler GW, Klein R, Wittorf A, Leyhe T, Richartz E,
Kohler N, Bartels M, Buchkremer G, Schott K: Increased BDNF serum
concentration in fibromyalgia with or without depression or
antidepressants. J Psychiatr Res 2007, 41:600–605.
28. Nugraha B, Korallus C, Gutenbrunner C: Serum level of brain-derived
neurotrophic factor in fibromyalgia syndrome correlates with depression
but not anxiety. Neurochem Int 2013, 62:281–286.
29. Haas L, Portela LV, Bohmer AE, Oses JP, Lara DR: Increased plasma levels of
brain derived neurotrophic factor (BDNF) in patients with fibromyalgia.
Neurochem Res 2010, 35:830–834.
30. Sarchielli P, Mancini ML, Floridi A, Coppola F, Rossi C, Nardi K, Acciarresi M,
Pini LA, Calabresi P: Increased levels of neurotrophins are not specific for
chronic migraine: evidence from primary fibromyalgia syndrome. J Pain
2007, 8:737–745.
31. Stefani LC, Torres IL, de Souza IC, Rozisky JR, Fregni F, Caumo W: BDNF as
an effect modifier for gender effects on pain thresholds in healthy
subjects. Neurosci Lett 2012, 514:62–66.
32. Maestu C, Cortes A, Vazquez JM, del Rio D, Gomez-Arguelles JM, del Pozo F,
Nevado A: Increased brain responses during subjectively-matched
mechanical pain stimulation in fibromyalgia patients as evidenced by
MEG. Clin Neurophysiol 2013, 124:752–760.
33. Diers M, Yilmaz P, Rance M, Thieme K, Gracely RH, Rolko C, Schley MT,
Kiessling U, Wang H, Flor H: Treatment-related changes in brain activation
in patients with fibromyalgia syndrome. Exp Brain Res 2012, 218:619–628.
34. Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, Clauw
DJ: Elevated insular glutamate in fibromyalgia is associated with
experimental pain. Arthritis Rheum 2009, 60:3146–3152.
35. Martinez-Jauand M, Sitges C, Rodriguez V, Picornell A, Ramon M, Buskila D,
Montoya P: Pain sensitivity in fibromyalgia is associated with catechol-O-
methyltransferase (COMT) gene. Eur J Pain 2013, 17:16–27.
36. Fuller-Thomson E, Nimigon-Young J, Brennenstuhl S: Individuals with
fibromyalgia and depression: findings from a nationally representative
Canadian survey. Rheumatol Int 2012, 32:853–862.
37. Giesecke T, Gracely RH, Williams DA, Geisser ME, Petzke FW, Clauw DJ: The
relationship between depression, clinical pain, and experimental pain in
a chronic pain cohort. Arthritis Rheum 2005, 52:1577–1584.
38. Schatzberg AF: The relationship of chronic pain and depression. J Clin
Psychiatry 2004, 65(Suppl 12):3–4.
39. Sairanen M, Lucas G, Ernfors P, Castren M, Castren E: Brain-derived
neurotrophic factor and antidepressant drugs have different but
coordinated effects on neuronal turnover, proliferation, and survival in
the adult dentate gyrus. J Neurosci 2005, 25:1089–1094.
40. Castro-Sánchez AM, Matarán-Peñarrocha GA, López-Rodríguez MM, Lara-
Palomo IC, Arendt-Nielsen L, Fernández-de-las-Peñas C: Gender differences
in pain severity, disability, depression, and widespread pressure pain
sensitivity in patients with fibromyalgia syndrome without comorbid
conditions. Pain Med 2012, 13:1639–1647.
41. Wolfe F, Walitt B: Culture, science and the changing nature of
fibromyalgia. Nat Rev Rheumatol 2013, 9:751–755.
42. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke
JP, Initiative S: The Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) statement: guidelines for reporting
observational studies. J Clin Epidemiol 2008, 61:344–349.
Zanette et al. Molecular Pain 2014, 10:46 Page 9 of 9
http://www.molecularpain.com/content/10/1/4643. Sehn F, Chachamovich E, Vidor LP, Dall-Agnol L, de Souza IC, Torres IL,
Fregni F, Caumo W: Cross-cultural adaptation and validation of the
Brazilian Portuguese version of the pain catastrophizing scale. Pain Med
2012, 13:1425–1435.
44. Bertolazi AN, Fagondes SC, Hoff LS, Dartora EG, Miozzo IC, de Barba ME,
Barreto SS: Validation of the Brazilian Portuguese version of the
Pittsburgh Sleep Quality Index. Sleep Med 2011, 12:70–75.
45. Marques AP, Santos AMB, Assumpção A, Matsutani LA, Lage LV, Pereira CAB:
Validação da versão brasileira do Fibromyalgia Impact Questionnaire
(FIQ). Rev Bras Reumatol 2006, 46:24–31.
46. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL,
Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ,
Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain
GA, Reynolds WJ, Romano TJ, Russel IJ, Sheon RP: The American College of
Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report
of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160–172.
47. A-priori Sample Size Calculator for Hierarchical Multiple Regression. http://
www.danielsoper.com/statcalc.
48. Katz MH: Multivariable Analysis: A Pratical Guide for Clinicians. New York:
Cambridge University Press; 1999.
doi:10.1186/1744-8069-10-46
Cite this article as: Zanette et al.: Higher serum S100B and BDNF levels
are correlated with a lower pressure-pain threshold in fibromyalgia.
Molecular Pain 2014 10:46.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
